...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy >Current Clinical Applications of Extracorporeal Photochemotherapy
【24h】

Current Clinical Applications of Extracorporeal Photochemotherapy

机译：体外光化学疗法的当前临床应用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

From the 1980s, extracorporeal photochemotherapy (ECP) has been shown to be effective in a variety of pathological conditions such as erythrodermic cutaneous T-cell lymphoma, autoimmune diseases, solid organ allograft rejection and graft versus host disease. To date, ECP represents a non-aggressive immune modulatory therapy with a low spectrum of toxicity. ECP reduces the alloreactivity promoting the immune tolerance to self. At the same time, it allows the maintenance of immune response integrity of both naive and memory T-cells. However, the molecular mechanisms of action by which ECP exerts its therapeutic activity are still under investigation. Here, we review molecular mechanisms and clinical applications involved in ECP. The outcome of ECP is difficult due to the lack of reliable predictor factors for the selection of patients and their adequate follow-up. Since the study of such predictors is important, we also describe some biological markers that enable us to investigate the clinical management of the patients considered for the use of ECP.
机译：从1980年代开始，体外光化学疗法（ECP）已被证明可在多种病理状况下有效，例如红皮病性皮肤T细胞淋巴瘤，自身免疫性疾病，同种异体器官排斥反应以及移植物抗宿主病。迄今为止，ECP代表了一种低毒性的非攻击性免疫调节疗法。 ECP减少了同种异体反应，从而增强了对自身的免疫耐受性。同时，它可以维持幼稚和记忆T细胞的免疫应答完整性。然而，ECP发挥其治疗活性的分子作用机理仍在研究中。在这里，我们回顾了ECP涉及的分子机制和临床应用。由于缺乏可靠的预测因素来选择患者并进行充分的随访，因此ECP的结果很困难。由于此类预测因子的研究很重要，因此我们还描述了一些生物学标记，这些标记使我们能够研究考虑使用ECP的患者的临床治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号